Australian Trial Shows Hybrid Closed-Loop Pumps Outperform Manual Insulin Dosing in Type 1 Diabetes

A study from Australia has delivered compelling evidence that hybrid closed-loop (HCL) insulin pump technology significantly outperforms traditional manual insulin dosing — and the findings have direct relevance for the millions of Americans living with Type 1 diabetes who still rely on injections or conventional pumps.

What Researchers Did

Scientists at the Department of Medicine, University of Melbourne recruited 120 Australian adults with Type 1 diabetes who were managing their condition either through multiple daily injections (MDI) or an insulin pump — but without continuous glucose monitoring (CGM). Participants were randomly assigned to either switch to the Medtronic 670G hybrid closed-loop system or continue their existing therapy for 26 weeks. The average participant was 44 years old, with a baseline HbA1c of 7.4%, and about half were using daily injections.

Key Findings

The primary goal was measuring time-in-range (TIR) — the percentage of each day spent with blood glucose between 70–180 mg/dL, the universally accepted healthy target range. Results were striking:

• The HCL group improved TIR from 55% to 70% — a 15-percentage-point jump over six months.
• The control group (continuing manual dosing) showed no change, remaining flat at 55%.
• HbA1c dropped by 0.4% in the HCL group (from approximately 7.4% to 7.0%), while controls saw no improvement.
• Participants using HCL also reported higher diabetes-specific positive well-being — feeling better about managing their condition — without any worsening of diabetes distress, sleep quality, or cognitive function.

Why an Australian Perspective Matters for US Patients

Australia's universal healthcare system means this study captured a realistic, diverse cross-section of adults — not just highly motivated early adopters. Australian diabetes management guidelines closely mirror those of the American Diabetes Association (ADA), making these results highly transferable. Importantly, the Medtronic 670G used in this trial is FDA-approved and widely available in the United States, meaning these findings aren't theoretical for American patients — they reflect a device already on the US market.

How This Compares to US Guidelines

The ADA currently recommends a TIR target of greater than 70% for most adults with Type 1 diabetes. At baseline, both groups in this study averaged just 55% TIR — well below that threshold. After six months with HCL, participants crossed the ADA's recommended target, reaching 70% TIR. The control group never got there. This gap underscores a critical point: technology, not just effort, may be necessary to meet modern glycemic standards.

Why This Matters for US Patients

Approximately 1.6 million Americans have Type 1 diabetes, and a significant portion still manage their condition with injections or older pump technology without CGM integration. This Australian trial demonstrates that upgrading to a hybrid closed-loop system can meaningfully improve blood sugar control and quality of life — simultaneously. If you're currently on MDI or a non-automated pump and struggling to hit your TIR goals, this research supports a conversation with your endocrinologist about whether closed-loop technology is right for you. Insurance coverage for HCL systems has also expanded considerably under Medicare and many private plans in recent years.

Study Citation

McAuley, Lee, Paldus et al. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. Diabetes Care, 2020. PMID: 33055139. DOI: 10.2337/dc20-1447